Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

242 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Drugs used in chemotherapy, such as mitomycin C and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as bacillus calmette-guerin (BCG) and interferon alfa, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether giving hyperthermia together with mitomycin C is more effective than giving BCG or standard therapy as second-line therapy in treating patients with recurrent bladder cancer.

PURPOSE: This randomized phase III trial is studying how well hyperthermia given together with mitomycin C works compared with BCG or standard therapy as second-line therapy in treating patients with recurrent bladder cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To determine whether hyperthermia in combination with mitomycin C versus bacillus Calmette-Guerin (BCG) or standard therapy as second-line therapy is effective in patients with recurrent non-muscle invasive bladder cancer following induction or maintenance therapy with BCG.
* To compare disease-free survival time in all patients.
* To compare complete response rate at 3 months in patients with carcinoma in situ.

Secondary

* To compare progression-free survival, overall survival, safety and tolerability of treatments, quality of life, cost, and cost-effectiveness in these patients.
* To assess biomarkers of response to standard and investigational treatment.

OUTLINE: This is a multicenter study. Patients are stratified according to presence of carcinoma in situ (yes vs no), prior bacillus Calmette-Guérin (BCG) therapy (induction vs maintenance), and participating center. Patients are randomized to 1 of 2 treatment arms.

* Arm I (experimental): Patients receive intravesical mitomycin C over two 30-minute instillations per session, and bladder hyperthermia (42 +/-2°C) is delivered in combination with each instillation. The suspension is maintained in the bladder for up to 2 hours. Treatment repeats once a week for 6 weeks followed by a 6-week rest period. Patients who are disease-free proceed to maintenance therapy consisting of one instillation of mitomycin C with bladder hyperthermia every 6 weeks for 1 year and then once every 8 weeks for 1 year. Patients who are disease-free at 24 months may continue treatment at the discretion of the clinician.
* Arm II (control): Patients receive 1 of the following treatment regimens depending on prior BCG treatment.

* Second course of BCG therapy (patients who failed previous induction BCG): Patients receive intravesical BCG (1 instillation) once a week for 6 weeks. The suspension is maintained in the bladder for up to 2 hours. Patients then receive maintenance therapy consisting of BCG once a week for 3 weeks in months 3, 6, 12, 18, and 24. Patients who are disease-free at 24 months may continue treatment at the discretion of the clinician.
* Standard therapy (patients who failed previous maintenance BCG): Patients receive standard therapy for BCG failure as defined by their treating centers. Standard therapy may include intravesical BCG alone, intravesical mitomycin C alone, intravesical epirubicin hydrochloride alone, or intravesical BCG in combination with interferon alpha.

All patients undergo cystoscopic surveillance with or without a biopsy every 3 months for 2 years. Urine, blood, and tissue samples are collected periodically for biomarker laboratory studies. Patients complete quality of life questionnaires (EORTC QLQ-BLS24, QLQ-C30, and EQ5D) at baseline, at 12 weeks, and at 6, 9, and 12 months.

After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

recurrent bladder cancer stage 0 bladder cancer stage I bladder cancer adenocarcinoma of the bladder squamous cell carcinoma of the bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BCG solution

Intervention Type BIOLOGICAL

recombinant interferon alfa

Intervention Type BIOLOGICAL

epirubicin hydrochloride

Intervention Type DRUG

mitomycin C

Intervention Type DRUG

laboratory biomarker analysis

Intervention Type OTHER

hyperthermia treatment

Intervention Type PROCEDURE

quality-of-life assessment

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of non-muscle invasive bladder cancer
* Recurrent disease after undergoing induction or maintenance therapy with bacillus Calmette-Guérin (BCG), meeting any 1 of the following criteria:

* Stage Ta or T1 disease (grade 2 or 3)
* Carcinoma in situ with stage Ta or T1 disease (grade 1, 2, or 3)
* Carcinoma in situ alone
* Has undergone a second resection of all T1 disease to exclude muscle invasive disease
* No urothelial cell carcinoma (UCC) ≥ T2
* No recurrence of grade 1 UCC following BCG induction therapy
* No UCC involving the prostatic urethra or upper urinary tract

PATIENT CHARACTERISTICS:

* WHO performance status 0-4
* WBC ≥ 3.0 x 10\^9/L
* Absolute neutrophil count ≥ 1.5 x 10\^9/L
* Hemoglobin ≥ 10 g/dL
* Platelet count ≥ 100 x 10\^9/L
* Serum creatinine \< 1.5 times upper limit of normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Normal kidneys and ureters on imaging CT scan within the past 12 months
* Available for long-term follow-up with a life expectancy of the duration of the trial
* Must be fit and willing to undergo a full or partial cystectomy
* No known or suspected reduced bladder capacity (\< 250 mL)
* No significant bleeding disorder
* No other malignancy within the past 5 years except nonmelanomatous skin cancer cured by excision, adequately treated carcinoma in situ of the cervix, or DCIS/LCIS of the breast
* No known allergy to mitomycin or bacillus Calmette-Guérin (BCG), or previously withdrawn from BCG treatment due to a related adverse event (e.g., systemic infection)
* No active or intractable urinary tract infection
* No urethral stricture or any situation impeding the insertion of a 20F catheter
* No bladder diverticula \> 1 cm
* No significant urinary incontinence
* No concurrent implanted electronic devices (e.g., cardiac pacemakers) or metallic implants within the pelvis, lower torso, spine, hip, or upper femur
* No immunocompromised state for any reason

PRIOR CONCURRENT THERAPY:

* At least 6 months since prior intravesical chemotherapy, except for single instillation post-transurethral resection
* No prior pelvic irradiation
* No prior hyperthermia in combination with intravesical mitomycin
* Concurrent participation in other studies allowed
* No current or long-term use of corticosteroids
* No concurrent chemotherapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Kelly, MD

Role: PRINCIPAL_INVESTIGATOR

University College London Hospitals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Basingstoke and North Hampshire NHS Foundation Trust

Basingstoke, England, United Kingdom

Site Status RECRUITING

Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

Birmingham, England, United Kingdom

Site Status RECRUITING

Leeds Cancer Centre at St. James's University Hospital

Leeds, England, United Kingdom

Site Status RECRUITING

University Hospitals of Leicester NHS Trust

Leicester, England, United Kingdom

Site Status RECRUITING

St. George's Hospital

London, England, United Kingdom

Site Status RECRUITING

University College of London Hospitals

London, England, United Kingdom

Site Status RECRUITING

South Manchester University Hospital

Manchester, England, United Kingdom

Site Status RECRUITING

James Cook University Hospital

Middlesbrough, England, United Kingdom

Site Status RECRUITING

University Hospital of Wales

Cardiff, Wales, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

Contact Person

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Tan WS, Panchal A, Buckley L, Devall AJ, Loubiere LS, Pope AM, Feneley MR, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths TRL, Page T, Hodgson D, Datta SN, Billingham LJ, Kelly JD. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Eur Urol. 2019 Jan;75(1):63-71. doi: 10.1016/j.eururo.2018.09.005. Epub 2018 Sep 28.

Reference Type DERIVED

PMID: 30274699 (View on PubMed)